Modern treatment options in epithelial ovarian carcinoma

被引：10

作者：

Benjamin, I ^{[1
]}

Rubin, SC ^{[1
]}

机构：

[1] Univ Penn Hlth Syst, Div Gynecol Oncol, Philadelphia, PA USA

来源：

CURRENT OPINION IN OBSTETRICS & GYNECOLOGY | 1998年 / 10卷 / 01期

关键词：

D O I：

10.1097/00001703-199802000-00006

中图分类号：

R71 [妇产科学];

学科分类号：

100211 ;

摘要：

Treatment options for epithelial ovarian cancers are under constant evolution. Recent advances have occurred in both first-line and second-line chemotherapeutic regimens. A newly published approach to first-line therapy incorporating intraperitoneal chemotherapy has demonstrated a benefit in selected patients. There are several new drugs showing activity in platinum-resistant epithelial ovarian cancer. 1040-872X (C) 1998 Rapid Science Publishers.

引用

页码：29 / 32

页数：4

共 19 条

[1] Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer
Alberts, DS
Liu, PY
Hannigan, EV
OToole, R
Williams, SD
Young, JA
Franklin, EW
ClarkePearson, DL
Malviya, VK
DuBeshter, B
Adelson, MD
Hoskins, WJ
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (26) : 1950 - 1955
[2] CARBOPLATIN DOSAGE - PROSPECTIVE EVALUATION OF A SIMPLE FORMULA BASED ON RENAL-FUNCTION
CALVERT, AH
NEWELL, DR
GUMBRELL, LA
OREILLY, S
BURNELL, M
BOXALL, FE
SIDDIK, ZH
JUDSON, IR
GORE, ME
WILTSHAW, E
[J]. JOURNAL OF CLINICAL ONCOLOGY, 1989, 7 (11) : 1748 - 1756
[3] Paclitaxel delivered as a 3-hr infusion with cisplatin in patients with gynecologic cancers: Unexpected incidence of neurotoxicity
Connelly, E
Markman, M
Kennedy, A
Webster, K
Kulp, B
Peterson, G
Belinson, J
[J]. GYNECOLOGIC ONCOLOGY, 1996, 62 (02) : 166 - 168
[4] Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: Results of a large European phase II study
Creemers, GJ
Bolis, G
Gore, M
Scarfone, G
Lacave, AJ
Guastalla, JP
Despax, R
Favalli, G
Kreinberg, R
VanBelle, S
Hudson, I
Verweij, J
Huinink, WWT
[J]. JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (12) : 3056 - 3061
[5] duBois A, 1997, SEMIN ONCOL, V24, P28
[6] Phase I/II study of the combination of carboplatin and paclitaxel as first-line chemotherapy in patients with advanced epithelial ovarian cancer
duBois, A
Luck, HJ
Bauknecht, T
Mobus, V
Bochtler, H
Diergarten, K
Meerpohl, HG
[J]. ANNALS OF ONCOLOGY, 1997, 8 (04) : 355 - 361
[7] Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer
Huinink, WTB
Gore, M
Carmichael, J
Gordon, A
Malfetano, J
Hudson, I
Broom, C
Scarabelli, C
Davidson, N
Spanczynski, M
Bolis, G
Malmstrom, H
Coleman, R
Fields, SC
Heron, JF
[J]. JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (06) : 2183 - 2193
[8] McGuire William P., 1997, Seminars in Oncology, V24, P13
[9] McGuire WP, 1996, SEMIN ONCOL, V23, P40
[10] Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer
McGuire, WP
Hoskins, WJ
Brady, MF
Kucera, PR
Partridge, EE
Look, KY
ClarkePearson, DL
Davidson, M
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (01) : 1 - 6

← 1 2 →